CSO Pamela Vig sold 30.6K shares (52.7% of holdings) at $34.00 for $1.0M; stock up 35.0% in 30 days.
Pamela Vig, Chief Scientific Officer, executed a substantial sale of 30,559 shares at $34.00 on 2024-06-24, reducing her holdings from 57,965 shares to 27,406 shares and realizing $1,039,006.00 in proceeds. This represents a 52.7% reduction in her post-transaction holdings. The sale occurred near the 52-week high ($34.93), with the stock currently trading at $33.14, and notably comes amid strong recent momentum: the stock has appreciated 35.0% over the trailing 30 days and 31.9% over 90 days. However, this momentum masks underlying weakness—the company reported negative net income of $-25,279,000.00 in its latest quarter and remains unprofitable on a full-year basis, despite impressive 141.8% annual revenue growth. A large divestiture by the company's top scientific officer while the stock is near 52-week highs and momentum is positive warrants investor attention, particularly given the company's current unprofitability trajectory.